📈 10M+ Views | 🚀 Turning Data into Actionable Insights | 🤖 AI, ML & Analytics Expert | 🎥 Content Creator & YouTuber | 💻 Power Apps Innovator | 🖼️ NFTs Advocate | 💡 Tech & Innovation Visionary | 🔔 Follow for More
New ETF, Tema Cardiovascular and Metabolic (HRTS), has been listed on Nasdaq, offering investors a chance to cash in on the Ozempic-fueled weight loss trend. The ETF contains positions in around 20 companies involved in anti-obesity and cardiovascular-related treatments, including Novo Nordisk and Eli Lilly. The popularity of thematic ETF investments has waned this year, with investors withdrawing $4.7 billion from such funds. On the other hand, GLP-1 drugs have had a significant impact on the biopharmaceutical space, with Novo Nordisk becoming Europe's largest company and Eli Lilly climbing to be among the top 10 S&P 500 companies. #ETF #Ozempic #WeightLoss #Investing
